isosorbide dinitrate has been researched along with hydralazine in 267 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 64 (23.97) | 18.7374 |
| 1990's | 40 (14.98) | 18.2507 |
| 2000's | 119 (44.57) | 29.6817 |
| 2010's | 39 (14.61) | 24.3611 |
| 2020's | 5 (1.87) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Sterz, H | 1 |
| Schrey, A | 1 |
| Brundage, BH; Chatterjee, K; Gelberg, H; Massie, B; Ports, TA; Rubin, S | 1 |
| Besse, P; Larnaudie, B; Page, A; Pic, A; Videau, P | 1 |
| Chatterjee, K; Greenberg, B; Hart, R; Massie, B; Parmley, WW; Werner, J | 1 |
| Manfrin, M; Prati, PL | 1 |
| Imhof, P | 1 |
| Cohn, JN; Franciosa, JA | 1 |
| Iturriaga, J; Lanas, F; Opazo, JA; Saavedra, J; Salvatici, R | 1 |
| Cohn, JN; Franciosa, JA; Pierpont, GL | 1 |
| Chatterjee, K; Drew, D; Klausner, SC; Parmley, WW; Polansky, J; Zacherle, B | 1 |
| Kelly, JG; Reynolds, GW; Richmond, A; Silke, B; Taylor, SH; Verma, SP | 1 |
| Isnard, R; Komajda, M; Lechat, P | 1 |
| Albanese, E; Chelimsky-Fallick, C; Fonarow, GC; Hamilton, MA; Luu, M; Moriguchi, JD; Stevenson, LW; Tillisch, JH; Walden, JA | 1 |
| Maev, IV; Vorob'ev, LP | 1 |
| Cohn, JN | 13 |
| Cobb, F; Cohn, JN; Dunkman, WB; Francis, G; Johnson, G; Loeb, H; Smith, R; Tristani, F; Wong, M; Ziesche, S | 1 |
| Hussain, M; Nelson, GI; Reynolds, GW; Richmond, A; Silke, B; Taylor, SH; Verma, SP | 1 |
| Gottlieb, SS; Kessler, PD; Lee, WH; Packer, M | 1 |
| Francis, GS | 1 |
| Moulds, RF | 1 |
| Levine, TB | 2 |
| Franciosa, JA | 2 |
| Hatano, M; Hibiya, K; Kaseda, N; Moriuchi, M; Ozawa, Y; Saito, S; Tamura, Y; Tokutake, E; Tsuji, M; Yumikura, S | 1 |
| Amaro Cendón, A; Gil de la Peña, M; González-Juanatey, JR; Vega Fernández, M | 1 |
| Bessegato, L; Dallan, L; de Moraes, AV; Grinberg, M; Higa, SS; Lavítola, Pde L; Pileggi, F; Sosa, EA | 1 |
| Archibald, DG; Cohn, JN; Dunkman, WB; Flohr, KH; Franciosa, JA; Francis, GS; Harston, WE; Jacobs, W; Tristani, FE; Ziesche, S | 2 |
| Burgess, JH; Chatterjee, K; Cousineau, D; Daly, P; Rouleau, JL | 1 |
| Gaĭdukova, NI; Kirichenko, LL; Solov'eva, FV | 1 |
| Parmley, WW | 1 |
| Schroeder, JS | 1 |
| Ruksin, VV | 1 |
| Gautieri, RF; Ward, CO | 1 |
| Haueisen, H; Kübler, W; Leinberger, H; Mäurer, W; Schuler, G | 1 |
| Shevchenko, VA | 1 |
| Ahuja, RC; Forsyth, DR; Nelson, GI; Silke, B; Taylor, SH; Verma, SP; Walker, C | 1 |
| Albani, A; Artese, D; Di Tomasso, E | 1 |
| Ciafone, RA | 1 |
| Hatano, M; Hibiya, K; Ichikawa, M; Nagasawa, M; Ozawa, Y; Saito, S; Tamura, Y; Tomobe, K; Yumikura, S | 1 |
| Richardson, PJ; Timmis, AD | 1 |
| Taylor, SH | 1 |
| Forsyth, DR; Hussain, M; Nelson, GI; Silke, B; Taylor, SH; Verma, SP | 1 |
| Kothiala, A; Mehta, NC; Patel, HR; Ramnani, K; Shah, CP | 1 |
| Leier, CV; Magorien, RD; Mehegan, JP; Unverferth, BJ; Unverferth, DV | 1 |
| Medina, N; Packer, M; Yushak, M | 1 |
| Haughom, F; Kramer, B; Massie, B | 1 |
| Baigrie, R; Burns, R; Feiglin, D; Haq, A; Hilton, D; McLaughlin, P; Rakowski, H; Tihal, H | 1 |
| Benetos, AM; Bouthier, JE; Levenson, JA; Safar, ME; Simon, AC | 1 |
| Chatterjee, K; Rouleau, JL | 1 |
| Gasanova, AS; Serbin, VI | 1 |
| Chatterjee, K; Parmley, WW; Rouleau, JL | 1 |
| Kolibash, AJ; Leier, CV; Magorien, RD; Robinson, JL | 1 |
| Bambach, D; Fontana, ME; Hermiller, JB; Huss, P; Leier, CV; Magorien, RD; Thompson, MJ; Unverferth, DV | 1 |
| Chesler, E; Pierpont, GL; Turner, GG; Weir, EK | 1 |
| Haughom, F; Kramer, B; Massie, BM; Shen, E | 1 |
| Greenberg, BH; Walsh, WF | 1 |
| Ferraro, N; Wilson, JR | 1 |
| Hirshfeld, J; Untereker, W; Wilson, JR | 1 |
| Ballantyne, D; Baxter, RH; Clark, RS; McGuinness, JB; Weir, JI | 1 |
| Packer, M | 1 |
| Cohn, JN; Franciosa, JA; Hale, KA; Pierpont, G | 1 |
| Desch, CE; Leier, CB; Magorien, RD; Thompson, MJ; Unverferth, DV | 1 |
| Das, SK; Randall, OS; Steffens, TG | 1 |
| Himmler, FC; Klein, G; Kutschera, I; Sauer, E; Schmidt, G; Wirtzfeld, A | 1 |
| Adams, ML; Cicero, TJ; Meyer, ER; Sewing, BN | 1 |
| Kawashima, A; Koike, H; Nishio, S; Ueno, Y | 1 |
| Baker, DW; Bottorff, M; Konstam, MA; Pitt, B | 1 |
| Akatsuka, N | 1 |
| Bhandari, B; Chakraborty, S; Ghose, JC; Mondal, M | 1 |
| Carson, PE; Cohn, JN; Dunkman, WB; Farrell, L; Fletcher, RD; Johnson, GR | 1 |
| Cohn, JN; Hughes, CV; Johnson, G; Wong, M | 1 |
| Cintron, G; Cobb, F; Cohn, JN; Francis, G; Johnson, G | 1 |
| Cintron, G; Cohn, JN; Francis, G; Goldman, S; Johnson, G; Smith, R | 1 |
| Carson, P; Cohn, JN; Francis, GS; Johnson, G | 1 |
| Cohn, JN; Francis, GS; Goldman, S; Johnson, G; Rector, TS; Simon, A | 1 |
| Carson, P; Cintron, GB; Cohn, JN; Fletcher, RD; Johnson, G; Orndorff, J | 1 |
| Cohn, JN; Fletcher, R; Johnson, GR; Loeb, H; Rector, T; Shabetai, R; Smith, R; Tristani, F | 1 |
| Cobb, FR; Cohn, JN; Johnson, G; Tristani, F; Ziesche, S | 1 |
| Bhat, G; Cohn, JN; Hughes, V; Johnson, G; Lopez, B; Shabetai, R; Wong, M | 1 |
| Cohn, JN; Daniels, G; Dunkman, WB; Farrell, L; Henrick, A; Johnson, G; Rector, TS; Smith, B | 1 |
| Cohn, JN; Cremo, R; Henrick, A; Johnson, G; Loeb, HS; Smith, R; Wilson, J | 1 |
| Bhat, G; Carson, PE; Cohn, JN; Dunkman, WB; Farrell, L; Johnson, GR | 1 |
| Carson, P; Cohn, J; Fletcher, R; Johnson, G | 1 |
| Cosín Aguilar, J; Cruz Fernández, JM; de Teresa Galván, E; Ferreira Montero, IJ; López-Sendón, J; Soler Soler, J; Tamargo Menéndez, J | 1 |
| Agostoni, P; Alimento, M; Contini, M; Guazzi, M; Marenzi, G | 1 |
| Chelimsky-Fallick, C; Fonarow, GC; Hamilton, MA; Kartashov, A; Moriguchi, JD; Steimle, AE; Stevenson, LW; Tillisch, JH | 1 |
| Adams, KF; Ellis, ML; Patterson, JH; Williamson, KM | 1 |
| Struthers, AD; Yee, KM | 1 |
| Adigun, AQ; Ajayi, AA; Ajayi, OE; Sofowora, GG | 1 |
| Carson, P; Cohn, JN; Johnson, G; Ziesche, S | 1 |
| Adragna, NC; Lauf, PK; Orlov, SN; White, RE | 1 |
| Aronow, WS | 2 |
| Craven, R | 1 |
| Cardin, S; Leung, TK; Li, D; Nattel, S; Pang, L; Shinagawa, K; Wang, Z | 1 |
| Rich, MW | 1 |
| Ferdinand, DP; Ferdinand, KC; Serrano, CC | 1 |
| Cohn, JN; Ferdinand, K; Franciosa, JA; Loscalzo, J; Ofili, E; Olukotun, A; Taylor, AL; Worcel, M; Yancy, CW; Ziesche, S | 1 |
| Cohn, JN; Franciosa, JA; Taylor, AL; Worcel, M | 1 |
| Gould, PA; Kaye, DM | 1 |
| Afzal, R; Anker, SD; Coats, AJ; Cohn, JN; Negassa, A; Poole-Wilson, PA; Yusuf, S | 1 |
| de Luca, L; Fedele, F; Gattis, WA; Gheorghiade, M; Klein, L; O'Connor, CM; Vitarelli, A; Zampino, M | 1 |
| Kahn, J | 6 |
| Chatterjee, K | 1 |
| Adams, K; Carson, P; Cohn, JN; D'Agostino, R; Ferdinand, K; Sabolinski, M; Taylor, AL; Taylor, M; Worcel, M; Yancy, C; Ziesche, S | 1 |
| Bloche, MG | 2 |
| Hare, JM | 1 |
| Tutton, R | 1 |
| Petsko, GA | 1 |
| Brandt, D | 1 |
| Payne, JW | 1 |
| Massie, BM | 1 |
| Duster, T | 2 |
| Cooper, RS; Moran, AE | 1 |
| Eisenberger, AB | 1 |
| Bellin, EY | 1 |
| Chow, AY | 1 |
| Peota, C | 1 |
| Bhopal, R; Rahemtulla, T | 1 |
| Saul, S | 4 |
| Wadman, M | 1 |
| Kahn, JD | 2 |
| Czap, A | 1 |
| Dunlap, ME; Ibrahim, OA | 1 |
| Thompson, CA | 1 |
| Senior, K | 1 |
| Bowser, R | 1 |
| Fiscella, K | 1 |
| Bitar, F; Elkayam, U | 1 |
| Puckrein, G; Yancy, CW | 1 |
| DeMaria, AN | 1 |
| Ferdinand, KC | 4 |
| Angus, DC; Ghali, JK; Linde-Zwirble, WT; Sabolinski, ML; Tam, SW; Villagra, VG; Winkelmayer, WC; Worcel, M | 1 |
| Gilbert, M; Laustsen, G; Wimett, L | 1 |
| Hoffman, S | 1 |
| Ruel, MD | 1 |
| Ginsburg, GS; Haga, SB | 1 |
| Aguiar-Souto, P; Garcia-Pavia, P; Ortigosa, FJ; Silva-Melchor, L | 1 |
| Cheng, JW | 1 |
| Puckrein, G | 1 |
| Adorisio, R; De Luca, L; Gheorghiade, M; Rossi, J | 1 |
| Cohn, JN; Feldman, AM; Janosko, K; McNamara, DM; Sabolinski, ML; Tam, SW; Taylor, AL; Tobelmann, P; Worcel, M | 1 |
| Adams, K; Cohn, JN; Lindenfeld, J; Mitchell, JE; Ofili, E; Sabolinski, ML; Tam, SW; Taylor, AL; Walsh, MN; Worcel, M; Ziesche, S | 1 |
| Bibbins-Domingo, K; Fernandez, A | 2 |
| Stockbridge, NL; Temple, R | 1 |
| Adams, KF; Anand, IS; Archambault, WT; Cohn, JN; Olukotun, AY; Rector, TS; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M | 1 |
| Flack, JM | 1 |
| Echols, MR; Yancy, CW | 1 |
| Adams, K; Carson, P; Cohn, JN; Ferdinand, K; Ofili, E; Olukotun, AY; Sabolinski, ML; Tam, SW; Taylor, AL; Taylor, M; Worcel, M; Yancy, CW; Ziesche, S | 1 |
| Colvin-Adams, M; Taylor, AL | 1 |
| Hoover, EL | 1 |
| Sade, RM | 1 |
| Matthews, GE | 1 |
| Anand, IS; Cohn, JN; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M | 1 |
| Crawley, L | 1 |
| Archambault, WT; Braman, VM; Franciosa, JA; Ghali, JK; Sabolinski, ML; Worcel, M; Yancy, CW | 1 |
| Cohn, JN; Packer, M; Sabolinski, ML; Tam, SW; Worcel, M | 1 |
| Decaro, MV; Graham, MG; Rosen, D | 1 |
| Cohn, JN; Curry, CL; Ferdinand, KC; Ghali, JK; Lindenfeld, J; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M | 1 |
| Daar, AS; Hardy, B; Séguin, B; Singer, PA | 1 |
| Huggett, B | 1 |
| Norgard, NB; Stark, JE | 1 |
| Dorr, GM; Jones, DS | 1 |
| Ellison, GT; Head, RF; Kahn, JD; Kaufman, JS; Martin, PA | 1 |
| Ashcroft, R; Ellison, GT; Martin, PA; Smart, A; Tutton, R | 1 |
| Reverby, SM | 1 |
| Caulfield, T; Harry, S | 1 |
| Münzel, T | 1 |
| Cohn, JN; Ghali, JK; Lindenfeld, J; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M | 1 |
| Fullerton, SM; Goering, S; Yu, JH | 1 |
| Holm, S | 1 |
| Jacob, RG; Thadani, U | 1 |
| Cohn, JN; Feldman, AM; Ghali, JK; Janosko, K; McNamara, DM; Ofili, E; Sabolinski, ML; Tam, SW; Taylor, AL; Tobelmann, P; Venkitachalam, L; Worcel, M; Yancy, C | 1 |
| Abrahams, Z; Francis, GS; Mullens, W; Sokos, G; Starling, RC; Tang, WH; Taylor, DO; Young, JB | 1 |
| Coons, SJ | 1 |
| Emsermann, CB; Fairclough, D; Hamman, R; Hammermeister, KE; Ho, M; Phibbs, S; Plomondon, M; Steiner, JF; Valuck, R; West, D | 1 |
| De Silva, DS; Izumiya, Y; Sam, F; Sato, K; Wilson, RM | 1 |
| Hsich, EM; Piña, IL | 1 |
| Dries, DL; McNamara, D; Rame, JE; Sabolinski, ML; Tam, SW; Worcel, M; Wu, AH | 1 |
| Ishizawar, D; Yancy, C | 1 |
| Bonham, VL; Cooper, LA; Frank, D; Gallagher, TH; Odunlami, AO; Price, EG; Sellers, SL | 1 |
| Feldman, A; Yancy, CW | 1 |
| Royal, CD; Rusert, BM | 1 |
| Butler, J; Cole, RT; Georgiopoulou, VV; Gheorghiade, M; Kalogeropoulos, AP; Quyyumi, A; Yancy, C | 1 |
| Cohn, JN; Mitchell, JE; O'Neal, W; Tam, SW; Taylor, AL; Trivedi, K; Worcel, M | 1 |
| Clark, M; Pan, L; Payne, J | 1 |
| Hare, JM; Mann, DL; Taylor, AL | 1 |
| Krimsky, S | 1 |
| Collier, R | 1 |
| Archambault, WT; Cohn, JN; Ghali, JK; Sabolinski, ML; Tam, SW; Taylor, AL; Worcel, M; Ziesche, S | 1 |
| Lim, WY; Woldman, S | 1 |
| Bhatt, DL; Butler, J; Fonarow, GC; Golwala, HB; Hernandez, AF; Liang, L; Stavrakis, S; Thadani, U; Yancy, CW | 1 |
| Eisen, HJ; Feitell, S; Hankins, SR | 1 |
| Colvin-Adams, M; Sharma, A; Yancy, CW | 1 |
| Anand, I; Elkayam, U; Feldman, AM; Ferdinand, KC; Leggett, C; Mancini, D; McNamara, D; Ofili, E; Piña, I | 1 |
| Anand, IS; Cohn, JN; Rector, TS; Taylor, AL; Win, S | 1 |
| Oliveira-Paula, GH | 1 |
| Butler, J; Cole, RT; Gupta, D | 1 |
| Bristow, MR | 1 |
| Cohn, JN; Feldman, AM; Hanley-Yanez, K; McNamara, DM; Tam, SW; Taylor, AL; Worcel, M; Yancy, CW | 1 |
| Bhatt, DL; Butler, J; Curtis, LH; Eapen, ZJ; Fonarow, GC; Heidenreich, PA; Hernandez, AF; Khazanie, P; Liang, L; Peterson, ED; Yancy, CW | 1 |
| Taylor, AL | 1 |
| Enseleit, F; Flammer, AJ; Naegele, M; Ruschitzka, F | 1 |
| Yee, J | 1 |
| Ba, SA; Cotter, G; Damasceno, A; Davison, BA; Dzudie, A; Edwards, C; Kouam, CK; Mayosi, BM; Milo, O; Mondo, C; Ogah, O; Ogola, E; Ojji, D; Sani, MU; Sliwa, K; Yonga, G | 1 |
| Butler, J; Konstam, MA | 1 |
| Adhyaru, B; Raj, L | 1 |
| Akers, S; Beraun, M; Chirinos, JA; Chittams, J; Haines, PG; Koppula, MR; Rawat, D; Segers, P; Shiva-Kumar, P; Soto-Calderon, H; Townsend, RR; Varakantam, S; Witschey, WR; Zamani, P | 1 |
| Akinboboye, O; Anand, I; Ofili, E; Puckrein, G; Williams, RA; Xu, L | 1 |
| Fonarow, GC; Heidenreich, PA; Ziaeian, B | 1 |
| Anand, IS; Arbit, B; Beri, N; Chang, KW; Clopton, P; Cohn, JN; Fox, S; Maisel, AS; Mojaver, S; Nguyen, NH; Tam, SW; Taylor, AL | 1 |
| Dékány, M; Muk, B; Nyolczas, N; Szabó, B | 1 |
| Demers, E; Girouard, C; Grégoire, JP; Kayibanda, JF; Moisan, J | 1 |
| Wu, A | 1 |
| Brewster, LM | 1 |
| Chakrapani, M; Kamath, A; Padakanti, A; Shenoy, A | 1 |
| Abdulla, J; Barasa, A; Bibby, BM; Bruun, NE; Brønnum-Schou, J; Bøtker, HE; Bøttcher, M; Dodt, K; Eiskjær, H; Gislason, G; Gustafsson, F; Hansen, VB; Hassager, C; Hollingdal, M; Høfsten, DE; Jonczy, B; Knudsen, AS; Kristensen, SL; Køber, L; Larsen, AH; Lomholdt, J; Madsen, JS; Mahboubi, K; Mellemkjær, S; Mikkelsen, KV; Møller, J; Nielsen, G; Nielsen, OW; Nørrelund, H; Poenaru, MP; Poulsen, MK; Raymond, I; Refsgaard, J; Schou, M; Serup-Hansen, K; Sillesen, K; Steffensen, FH; Torp-Petersen, C; Vraa, S; Wiggers, H | 1 |
| Amar, M; Faulkenberg, K; Lam, SW; Perez, A; Tang, WHW; Williams, JB | 1 |
| Guglin, M; Ilonze, OJ | 1 |
| Akinniyi, D; Callier, SL; McPartland, K; Payne, PW; Richardson, TL; Rothstein, MA; Royal, CDM | 1 |
| Ahmad, FS; Ahmad, T; Allen, LA | 1 |
55 review(s) available for isosorbide dinitrate and hydralazine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[New aspects in the treatment of acute cardiac insufficiency].
Topics: Adrenergic beta-Antagonists; Clonidine; Diazoxide; Digitalis Glycosides; Diuretics; Droperidol; Fentanyl; Fibrinolytic Agents; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Microcirculation; Myocardial Contraction; Neuroleptanalgesia; Nitroprusside; Phentolamine; Prazosin; Respiration, Artificial; Vascular Resistance; Vasodilator Agents | 1978 |
[Vasodilator agents in the treatment of heart failure].
Topics: Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Minoxidil; Nitroglycerin; Nitroprusside; Phentolamine; Prazosin; Vasodilator Agents | 1978 |
[Treatment of cardiac failure with vasodilators (author's transl)].
Topics: Cardiac Glycosides; Diuretics; Drug Therapy, Combination; Heart Failure; Hydralazine; Hypotension; Isosorbide Dinitrate; Nitroglycerin; Nitroprusside; Phenoxybenzamine; Phentolamine; Prazosin; Vasodilator Agents | 1978 |
[Nitrate derivatives and cardiac insufficiency].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Drug Tolerance; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Middle Aged | 1992 |
Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure.
Topics: Enalapril; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Prazosin; Survival Rate; Vasodilator Agents | 1991 |
Studies of Left Ventricular Dysfunction (SOLVD)--new hope for heart failure.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Hospitalization; Humans; Hydralazine; Isosorbide Dinitrate; Stroke Volume; Survival Rate | 1991 |
Heart failure management: the impact of drug therapy on survival.
Topics: Captopril; Clinical Trials as Topic; Digitalis Glycosides; Diuretics; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Time Factors | 1988 |
Role of isosorbide dinitrate in management of chronic congestive heart failure.
Topics: Administration, Oral; Chronic Disease; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Heart Failure; Heart Rate; Humans; Hydralazine; Isosorbide Dinitrate; Myocardial Contraction; Stroke Volume | 1985 |
Combination therapy with isosorbide dinitrate: current status and the future.
Topics: Angina Pectoris; Coronary Vasospasm; Diltiazem; Drug Therapy, Combination; Esophageal Achalasia; Exercise Test; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nifedipine; Nitroprusside; Propranolol; Verapamil | 1985 |
Current concepts in the treatment of congestive heart failure.
Topics: Calcium Channel Blockers; Captopril; Digitalis Glycosides; Dipeptides; Diuretics; Enalapril; Enzyme Inhibitors; Heart Failure; Humans; Hydralazine; Hypernatremia; Isosorbide Dinitrate; Nitroprusside; Prazosin; Vasoconstriction | 1984 |
[Treatment of heart failure in ischemic heart disease with beta-adrenostimulators and peripheral vasodilators].
Topics: Adrenergic beta-Agonists; Captopril; Cardiotonic Agents; Coronary Disease; Dobutamine; Dopamine; Heart Failure; Humans; Hydralazine; Isoproterenol; Isosorbide Dinitrate; Nitroprusside; Nonachlazine; Phentolamine; Practolol; Prazosin; Prenalterol; Vasodilator Agents | 1983 |
Vasodilator therapy of congestive heart failure.
Topics: Aortic Valve Insufficiency; Captopril; Dobutamine; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Minoxidil; Mitral Valve Insufficiency; Nitroglycerin; Nitroprusside; Phentolamine; Physical Exertion; Piperazines; Prazosin; Quinazolines; Time Factors; Vasodilator Agents | 1980 |
[Peripheral vasodilators in the treatment of heart failure].
Topics: Cardiac Output; Cardiomyopathies; Coronary Circulation; Droperidol; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitrates; Nitroprusside; Phentolamine; Piperazines; Prazosin; Quinazolines; Rheumatic Heart Disease; Stroke Volume; Vasodilator Agents | 1982 |
Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Enalapril; Exercise; Felodipine; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Norepinephrine; Oxygen Consumption; Prognosis; Stroke Volume; Survival Analysis | 1994 |
Plasma norepinephrine and mortality.
Topics: Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Norepinephrine; Prognosis; Sympathetic Nervous System; Ventricular Dysfunction, Left | 1995 |
Management of heart failure. I. Pharmacologic treatment.
Topics: Angiotensin-Converting Enzyme Inhibitors; Decision Support Techniques; Digoxin; Diuretics; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; United States; United States Agency for Healthcare Research and Quality; Ventricular Dysfunction, Left | 1994 |
[Vasodilator therapy in cardiac failure].
Topics: Adrenergic beta-Antagonists; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitroglycerin; Norepinephrine; Renin-Angiotensin System; Sympathetic Nervous System; Vasodilator Agents | 1993 |
[Neurohormonal factors in heart failure. I].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Autonomic Nervous System; Clinical Trials as Topic; Female; Heart; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Receptors, Adrenergic; Renin-Angiotensin System; Vasodilator Agents | 1996 |
Can drug effects on mortality in heart failure be predicted by any surrogate measure?
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Biomarkers; Calcium Channel Blockers; Deoxyepinephrine; Dopamine Agonists; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate | 1997 |
Left ventricle and arteries: structure, function, hormones, and disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arginine Vasopressin; Drug Combinations; Epinephrine; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitroprusside; Prazosin; Randomized Controlled Trials as Topic; Renin; Renin-Angiotensin System; Stroke Volume; Survival Analysis; Time Factors; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Remodeling | 2001 |
Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
Topics: Adrenergic beta-Antagonists; Aged; Aging; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Clinical Trials as Topic; Diagnosis, Differential; Diastole; Digoxin; Diuretics; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prevalence; Prognosis; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Stroke Volume; Ventricular Dysfunction, Left | 2001 |
Management of heart failure in the elderly.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Digoxin; Diuretics; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Patient Education as Topic; Self Care | 2002 |
Contemporary treatment of heart failure: is there adequate evidence to support a unique strategy for African-Americans? Con position.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African American; Black People; Clinical Trials as Topic; Coronary Disease; Heart Failure; Humans; Hydralazine; Hypertension; Isosorbide Dinitrate; Risk Factors | 2002 |
Clinical treatment regimens for chronic heart failure: a review.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiotonic Agents; Digoxin; Diuretics; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Pacemaker, Artificial; Spironolactone; Vasodilator Agents | 2002 |
Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Cardiotonic Agents; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Systole; Vasodilator Agents | 2003 |
Congestive heart failure: what should be the initial therapy and why?
Topics: Adrenergic Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Therapy, Combination; Exercise; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Vasodilator Agents | 2002 |
How a drug becomes "ethnic": law, commerce, and the production of racial categories in medicine.
Topics: Black or African American; Cardiovascular Agents; Commerce; Drug Approval; Drug Combinations; Drug Labeling; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Retrospective Studies; United States | 2004 |
Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?
Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Mineralocorticoid Receptor Antagonists; Piperazines; Pyridines; Ranolazine; Tetrazoles; Tolvaptan; Vasodilator Agents | 2005 |
Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial.
Topics: Animals; Black or African American; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Heart Function Tests; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Risk Assessment; Severity of Illness Index; Stroke Volume; Survival Rate; Treatment Outcome | 2005 |
Isosorbide dinitrate and hydralazine hydrochloride: a review of efficacy and safety.
Topics: Black or African American; Cardiac Output, Low; Drug Combinations; Humans; Hydralazine; Isosorbide Dinitrate | 2005 |
A-HeFT: old dog, new endothelial tricks.
Topics: Black or African American; Drug Therapy, Combination; Endothelium, Vascular; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Treatment Outcome; United States; Vasodilator Agents | 2005 |
A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination.
Topics: Black People; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitric Oxide Donors; Randomized Controlled Trials as Topic; Vasodilator Agents | 2006 |
Pharmacological treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Digitalis Glycosides; Diuretics; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Mineralocorticoid Receptor Antagonists | 2006 |
Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure.
Topics: Cardiac Output, Low; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitric Oxide; Nitric Oxide Donors | 2006 |
Medicalisation of race.
Topics: Age Distribution; Aged; Antineoplastic Agents; Black or African American; Clinical Trials as Topic; Drug Approval; Drug Combinations; Gefitinib; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Lung Neoplasms; Middle Aged; Patents as Topic; Quinazolines; United States; United States Food and Drug Administration | 2007 |
Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure.
Topics: Black or African American; Disease Progression; Drug Combinations; Endothelium, Vascular; Genetic Predisposition to Disease; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitric Oxide; Oxidative Stress; Patient Selection; Severity of Illness Index; Treatment Outcome; Vasodilator Agents | 2006 |
Isosorbide dinitrate-hydralazine improves outcomes in African Americans with heart failure.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Treatment Outcome; United States | 2007 |
African American heart failure trial: role of endothelial dysfunction and heart failure in African Americans.
Topics: Adult; Aged; Black or African American; Drug Therapy, Combination; Endothelium, Vascular; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Middle Aged; Nitric Oxide Donors; Randomized Controlled Trials as Topic | 2007 |
Evidence-based treatment of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Defibrillators, Implantable; Digitalis Glycosides; Diuretics; Drug Combinations; Evidence-Based Medicine; Exercise; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Mineralocorticoid Receptor Antagonists; Vasodilator Agents | 2007 |
Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Mineralocorticoid Receptor Antagonists; Prescription Fees; Renin-Angiotensin System; Ventricular Dysfunction, Left | 2008 |
Fixed-dose isosorbide dinitrate-hydralazine: race-based cardiovascular medicine benefit or mirage?
Topics: Black or African American; Black People; Drug Combinations; Evidence-Based Medicine; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Vasodilator Agents | 2008 |
Genotyping the future: scientists' expectations about race/ ethnicity after BiDil.
Topics: Drug Combinations; Genetics, Population; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Pharmacogenetics; Racial Groups; Sex; Vasodilator Agents | 2008 |
[Recent findings on nitrates: their action, bioactivation and development of tolerance].
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; Coronary Disease; Drug Tolerance; Endothelium, Vascular; Guanylate Cyclase; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Molsidomine; Nitrates; Nitric Oxide; Nitric Oxide Donors; Nitroglycerin; Oxidative Stress; Pentaerythritol Tetranitrate; Reactive Oxygen Species; Vasodilation; Vasodilator Agents | 2008 |
Heart failure in women: a need for prospective data.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiac Pacing, Artificial; Digoxin; Female; Heart Failure; Heart-Assist Devices; Humans; Hydralazine; Isosorbide Dinitrate; Male; Mineralocorticoid Receptor Antagonists; Pacemaker, Artificial; Platelet Aggregation Inhibitors; Risk Factors; Sex Factors; Women's Health | 2009 |
Racial differences in heart failure therapeutics.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitric Oxide; Nitric Oxide Donors; Phenotype; Polymorphism, Genetic; Renin-Angiotensin System; Risk Assessment; United States | 2010 |
Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions.
Topics: Animals; Black or African American; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Exercise Tolerance; Forecasting; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Stroke Volume | 2011 |
Pharmacological management of chronic heart failure: old drugs, new drugs and new indications.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiovascular Agents; Chronic Disease; Digoxin; Drug Combinations; Heart Failure; Heart Failure, Systolic; Humans; Hydralazine; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists | 2013 |
Adjunctive therapy and management of the transition of care in patients with heart failure.
Topics: Adaptation, Psychological; Adrenergic beta-Antagonists; Alcohol Drinking; Ambulatory Care; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Resynchronization Therapy; Cardiotonic Agents; Continuity of Patient Care; Defibrillators, Implantable; Deinstitutionalization; Diet; Digoxin; Diuretics; Drug Combinations; Exercise Therapy; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Mineralocorticoid Receptor Antagonists; Palliative Care; Risk Reduction Behavior; Secondary Prevention; Self Care; Smoking Cessation; Substance-Related Disorders | 2014 |
Heart failure in African Americans: disparities can be overcome.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African American; Cardiotonic Agents; Defibrillators, Implantable; Digoxin; Drug Combinations; Health Status Disparities; Heart Failure; Heart Transplantation; Heart-Assist Devices; Humans; Hydralazine; Hypertension; Incidence; Isosorbide Dinitrate; Mineralocorticoid Receptor Antagonists; Prevalence; Quality of Health Care; Socioeconomic Factors; Vasodilator Agents | 2014 |
Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Practice Guidelines as Topic | 2014 |
Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiotonic Agents; Cardiovascular Agents; Digoxin; Diuretics; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists; Neprilysin; Stroke Volume; Vasodilator Agents | 2016 |
An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF).
Topics: Adrenergic beta-Antagonists; American Heart Association; Amides; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Antihypertensive Agents; Atrial Natriuretic Factor; Benzazepines; Biphenyl Compounds; Calcium Channel Blockers; Cardiology; Cardiotonic Agents; Cardiovascular Agents; Digoxin; Diuretics; Drug Combinations; Erythropoietin; Evidence-Based Medicine; Fumarates; Heart Failure; Hematinics; Humans; Hydralazine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Isosorbide Dinitrate; Ivabradine; Mineralocorticoid Receptor Antagonists; Peptide Fragments; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Societies, Medical; Stroke Volume; Tetrazoles; United States; Valsartan; Vasodilator Agents | 2016 |
Combination of Hydralazine and Isosorbide-Dinitrate in the Treatment of Patients with Heart Failure with Reduced Ejection Fraction.
Topics: Clinical Trials as Topic; Drug Interactions; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Stroke Volume | 2018 |
Heart Failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Cardiac Rehabilitation; Cardiovascular Agents; Coronary Artery Disease; Defibrillators, Implantable; Diabetes Complications; Diagnostic Techniques, Cardiovascular; Digoxin; Diuretics; Heart Failure; Hospitalization; Humans; Hydralazine; Hypertension; Isosorbide Dinitrate; Ivabradine; Life Style; Mineralocorticoid Receptor Antagonists; Palliative Care; Primary Prevention; Referral and Consultation; Risk Factors | 2018 |
57 trial(s) available for isosorbide dinitrate and hydralazine
| Article | Year |
|---|---|
Immediate effects of hydralazine-isosorbide dinitrate combination on exercise capacity and exercise hemodynamics in patients with left ventricular failure.
Topics: Adult; Aged; Drug Therapy, Combination; Exercise Test; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Middle Aged | 1979 |
Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial.
Topics: Actuarial Analysis; Captopril; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Time Factors | 1992 |
[Effects of corinfar, nitrosorbide and apressin on external respiration and blood flow in chronic obstructive bronchitis].
Topics: Blood Circulation; Bronchitis; Humans; Hydralazine; Hypertension, Pulmonary; Isosorbide Dinitrate; Nifedipine; Pulmonary Circulation; Pulmonary Heart Disease; Respiration; Respiratory Function Tests | 1992 |
V-HeFT positive for enalapril.
Topics: Adolescent; Adult; Aged; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged | 1991 |
Studies of Left Ventricular Dysfunction (SOLVD)--new hope for heart failure.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Hospitalization; Humans; Hydralazine; Isosorbide Dinitrate; Stroke Volume; Survival Rate | 1991 |
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Chronic Disease; Death, Sudden; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Enalapril; Heart Failure; Hospitalization; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Norepinephrine; Oxygen Consumption; Patient Compliance; Physical Exertion; Stroke Volume; Survival Rate | 1991 |
Statistical significance of Veterans Administration Vasodilator Heart Failure Trial results.
Topics: Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Prazosin; Research Design; Statistics as Topic; United States; United States Department of Veterans Affairs | 1990 |
First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function.
Topics: Adult; Aged; Clinical Trials as Topic; Diuretics; Furosemide; Heart Ventricles; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Myocardial Infarction; Prenalterol; Prospective Studies; Random Allocation; Stimulation, Chemical; Vasodilator Agents | 1987 |
Heart failure management: the impact of drug therapy on survival.
Topics: Captopril; Clinical Trials as Topic; Digitalis Glycosides; Diuretics; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Time Factors | 1988 |
Role of vasodilators in the treatment of congestive heart failure.
Topics: Captopril; Clinical Trials as Topic; Dipeptides; Double-Blind Method; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Prazosin; Random Allocation; Regional Blood Flow; Vascular Resistance; Vasodilator Agents | 1985 |
Effect of vasodilator therapy on mortality in chronic congestive heart failure.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Prazosin; Random Allocation | 1988 |
[Comparative study of vasodilator drugs in heart valve diseases].
Topics: Adolescent; Adult; Aortic Valve Insufficiency; Clinical Trials as Topic; Echocardiography; Female; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Mitral Valve Insufficiency; Prazosin; Vasodilator Agents | 1987 |
Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Exercise Test; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prazosin; Random Allocation; Vasodilator Agents | 1986 |
Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prazosin; Prognosis; Random Allocation | 1987 |
Dose-dependent haemodynamic response to prenalterol in patients with congestive heart failure.
Topics: Administration, Oral; Adrenergic beta-Agonists; Cardiac Catheterization; Cardiac Output; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epinephrine; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Norepinephrine; Practolol; Prenalterol; Pulmonary Wedge Pressure; Stroke Volume | 1982 |
Hemodynamic trial of sequential treatment with diuretic, vasodilator, and positive inotropic drugs in left ventricular failure following acute myocardial infarction.
Topics: Adrenergic beta-Agonists; Adult; Cardiotonic Agents; Drug Therapy, Combination; Furosemide; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Myocardial Infarction; Practolol; Prenalterol; Random Allocation | 1984 |
Hemodynamic comparison of primary venous or arteriolar dilatation and the subsequent effect of furosemide in left ventricular failure after acute myocardial infarction.
Topics: Adult; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Furosemide; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Myocardial Infarction; Random Allocation; Stroke Volume; Vascular Resistance | 1983 |
Regression of myocardial cellular hypertrophy with vasodilator therapy in chronic congestive heart failure associated with idiopathic dilated cardiomyopathy.
Topics: Aged; Cardiomyopathy, Hypertrophic; Drug Combinations; Female; Heart; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Myocardium | 1983 |
Circulatory improvement after hydralazine or isosorbide dinitrate administration in patients with heart failure. Effect on metabolic responses to submaximal exercise.
Topics: Adult; Aged; Cardiac Output; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Lactates; Male; Middle Aged; Oxygen Consumption; Physical Exertion | 1981 |
[Orally active vasodilators in the management of chronic treatment-resistant cardiac failure (author's transl)].
Topics: Adult; Aged; Dihydralazine; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Middle Aged; Prazosin; Quinazolines | 1980 |
Plasma norepinephrine and mortality.
Topics: Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Norepinephrine; Prognosis; Sympathetic Nervous System; Ventricular Dysfunction, Left | 1995 |
Effect of vasodilator therapy on mortality in chronic congestive heart failure.
Topics: Adult; Aged; Captopril; Chi-Square Distribution; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Vasodilation; Vasodilator Agents | 1993 |
The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Prazosin; Research Design; Survival Analysis; Vasodilator Agents | 1993 |
The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group.
Topics: Atrial Fibrillation; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Morbidity; Prazosin; Prognosis; Risk Factors | 1993 |
Influence of age on mechanisms and prognosis of heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Age Factors; Aged; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prazosin; Prognosis; Survival Analysis | 1993 |
Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prazosin; Prognosis; Stroke Volume; Survival Analysis; Ventricular Function, Left | 1993 |
Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group.
Topics: Cause of Death; Death, Sudden, Cardiac; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prazosin; Risk Factors; Survival Analysis | 1993 |
Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Risk Factors; Survival Analysis | 1993 |
Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Norepinephrine; Renin; Risk Factors; Survival Analysis | 1993 |
Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group.
Topics: Death, Sudden, Cardiac; Drug Therapy, Combination; Electrocardiography, Ambulatory; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prevalence; Risk Factors; Tachycardia, Ventricular | 1993 |
Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Arrhythmias, Cardiac; Cardiomegaly; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Norepinephrine; Oxygen Consumption; Prazosin; Prognosis; Stroke Volume; Ventricular Function, Left | 1993 |
Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Topics: Anaerobic Threshold; Drug Therapy, Combination; Enalapril; Exercise Test; Exercise Tolerance; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prazosin | 1993 |
Echocardiographic variables as prognostic indicators and therapeutic monitors in chronic congestive heart failure. Veterans Affairs cooperative studies V-HeFT I and II. V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Echocardiography; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prazosin; Survival Analysis; Ventricular Function, Left | 1993 |
Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. V-HeFT II. The V-HeFT VA Cooperative Studies Group.
Topics: Attitude to Health; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Quality of Life; Surveys and Questionnaires | 1993 |
Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Drug Therapy, Combination; Enalapril; Heart Failure; Hospitalization; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prazosin; Risk Factors; Time Factors | 1993 |
Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group.
Topics: Cerebrovascular Disorders; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Incidence; Isosorbide Dinitrate; Male; Middle Aged; Platelet Aggregation Inhibitors; Prazosin; Thromboembolism; Warfarin | 1993 |
Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT)
Topics: Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Middle Aged; Prognosis; Stroke Volume; Systole; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left | 1996 |
Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood-Air Barrier; Bradykinin; Cyclooxygenase Inhibitors; Diffusion; Double-Blind Method; Enalapril; Epoprostenol; Exercise Test; Female; Heart Failure; Humans; Hydralazine; Hypertension; Isosorbide Dinitrate; Male; Middle Aged; Peptidyl-Dipeptidase A; Pulmonary Alveoli; Pulmonary Circulation; Pulmonary Gas Exchange; Respiratory Function Tests | 1997 |
Vasodilator therapy of hypertensive acute left ventricular failure: comparison of captopril-prazosin with hydralazine-isosorbide dinitrate.
Topics: Adult; Antihypertensive Agents; Captopril; Drug Therapy, Combination; Female; Humans; Hydralazine; Hypertension; Isosorbide Dinitrate; Male; Middle Aged; Prazosin; Prospective Studies; Single-Blind Method; Vasodilator Agents; Ventricular Dysfunction, Left | 1998 |
Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Double-Blind Method; Drug Therapy, Combination; Enalapril; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Norepinephrine; Renin; Retrospective Studies; Survival Rate; Treatment Outcome; Vasodilator Agents; White People | 1999 |
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology.
Topics: Adolescent; Adult; Aged; Black People; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Hydralazine; Informed Consent; Isosorbide Dinitrate; Male; Middle Aged; Patient Selection; Research Design; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left | 2002 |
The African-American Heart Failure Trial: background, rationale and significance.
Topics: Black or African American; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Research Design | 2002 |
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Adult; Aged; Black People; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Nitric Oxide Donors; Quality of Life; Survival Analysis; Treatment Outcome; Vasodilator Agents | 2004 |
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
Topics: Adult; Aged; Arthralgia; Biomarkers; Black or African American; Cardiovascular Agents; Cause of Death; Disease-Free Survival; Dizziness; Double-Blind Method; Drug Combinations; Heart Failure; Heart Transplantation; Hospitalization; Humans; Hydralazine; Hypotension; Isosorbide Dinitrate; Kaplan-Meier Estimate; Middle Aged; Mortality; Natriuretic Peptide, Brain; Nitric Oxide Donors; Proportional Hazards Models; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Vasodilator Agents | 2007 |
Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT.
Topics: Adult; Aged; Black or African American; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Natriuretic Peptide, Brain; Stroke Volume; Treatment Outcome; Ultrasonography; Ventricular Remodeling | 2007 |
Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial).
Topics: Administration, Oral; Black or African American; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Patient Compliance; Quality of Life; Stroke Volume; Survival Rate; Treatment Outcome; United States | 2007 |
Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Topics: Adolescent; Adult; Area Under Curve; Biological Availability; Capsules; Cross-Over Studies; Dosage Forms; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydralazine; Isosorbide Dinitrate; Male; Tablets; Therapeutic Equivalency; Vasodilator Agents | 2007 |
Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black or African American; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Treatment Outcome; Vasodilator Agents | 2007 |
Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial.
Topics: Black People; Blood Pressure; Diastole; Drug Combinations; Female; Gene Frequency; Genotype; Heart Failure; Humans; Hydralazine; Introns; Isosorbide Dinitrate; Male; Middle Aged; Nitric Oxide Synthase Type III; Phenotype; Polymorphism, Genetic; Promoter Regions, Genetic; Stroke Volume; Vasodilator Agents; White People | 2009 |
Atrial fibrillation and mortality in African American patients with heart failure: results from the African American Heart Failure Trial (A-HeFT).
Topics: Atrial Fibrillation; Black or African American; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Hydralazine; Incidence; Isosorbide Dinitrate; Male; Middle Aged; Prevalence; Prognosis; Quality of Life; Risk Factors; Stroke Volume; Survival Rate; United States | 2011 |
Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial.
Topics: Age Factors; Aged; Aging; Black or African American; Double-Blind Method; Drug Therapy, Combination; Female; Health Status Indicators; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Kaplan-Meier Estimate; Male; Middle Aged; Nitric Oxide Donors; Quality of Life; Time; Treatment Outcome; United States; Vasodilator Agents | 2012 |
Effect of fixed-dose combination of isosorbide dinitrate and hydralazine on all hospitalizations and on 30-day readmission rates in patients with heart failure: results from the African-American Heart Failure Trial.
Topics: Black or African American; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Patient Readmission; Recurrence; Survival Rate; Time Factors; Treatment Outcome; United States | 2014 |
G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.
Topics: Analysis of Variance; Black or African American; Disease-Free Survival; Drug Combinations; Female; Genotype; Heart Failure; Heterotrimeric GTP-Binding Proteins; Humans; Hydralazine; Isosorbide Dinitrate; Length of Stay; Male; Middle Aged; Polymorphism, Single Nucleotide; Quality of Life; Treatment Outcome; Vasodilator Agents; Ventricular Dysfunction, Left | 2014 |
Bi treatment with hydralazine/nitrates vs. placebo in Africans admitted with acute HEart Failure (BA-HEF).
Topics: Acute Disease; Adult; Africa South of the Sahara; Aged; Black People; Double-Blind Method; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Middle Aged; Prospective Studies; Vasodilator Agents | 2016 |
Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction.
Topics: Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Echocardiography, Doppler; Female; Fibrosis; Heart Failure; Heart Ventricles; Humans; Hydralazine; Hypertrophy, Left Ventricular; Isosorbide Dinitrate; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardium; Pilot Projects; Stroke Volume; Vasodilator Agents; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Heart Failure With Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure Trial.
Topics: Adrenergic beta-Antagonists; Black or African American; Cause of Death; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prevalence; Recovery of Function; Stroke Volume; Time Factors; Treatment Outcome; United States; Vasodilator Agents; Ventricular Function, Left | 2018 |
The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chr
Topics: Aged; Chronic Disease; Denmark; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Female; Heart Failure; Hospitalization; Humans; Hydralazine; Hypoglycemic Agents; Isosorbide Dinitrate; Male; Metformin; Myocardial Infarction; Placebos; Prediabetic State; Stroke; Stroke Volume | 2021 |
158 other study(ies) available for isosorbide dinitrate and hydralazine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[New nitrate indications].
Topics: Dihydralazine; Drug Combinations; Heart Diseases; Humans; Hydralazine; Isosorbide Dinitrate; Myocardial Infarction; Nitrates; Nitroglycerin; Nitroprusside; Phentolamine; Vasodilator Agents | 1978 |
Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Lupus Erythematosus, Systemic; Nitroglycerin; Physical Exertion; Prazosin; Pressure; Rest; Time Factors; Vasodilator Agents | 1978 |
[Hemodynamic effects of oral dihydralazine and sublingual isosorbide dinitrate, alone and in combination in chronic heart failure].
Topics: Administration, Oral; Aged; Chronic Disease; Dihydralazine; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Mouth Floor | 1979 |
Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Nitroglycerin; Vascular Resistance; Vasodilator Agents | 1977 |
[Treatment of advanced heart failure with hydralazine and isosorbide dinitrate (author's transl)].
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazine; Isosorbide; Isosorbide Dinitrate; Male; Middle Aged | 1979 |
Combined oral hydralazine-nitrate therapy in left ventricular failure. Hemodynamic equivalency to sodium nitroprusside.
Topics: Administration, Oral; Aged; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydralazine; Infusions, Parenteral; Isosorbide Dinitrate; Middle Aged; Nitroprusside; Vascular Resistance | 1978 |
Use of vasodilator drugs in congestive heart failure.
Topics: Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitroprusside; Prazosin; Vasodilator Agents | 1978 |
Combination vasodilator therapy for severe chronic congestive heart failure.
Topics: Chronic Disease; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Minoxidil; Nitroglycerin; Nitroprusside; Vasodilator Agents | 1976 |
Vasodilator therapy for acute heart failure: haemodynamic comparison of hydralazine/isosorbide, alpha-adrenoceptor blockade, and angiotensin-converting enzyme inhibition.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Doxazosin; Drug Therapy, Combination; Enalaprilat; Heart Rate; Hemodynamics; Humans; Hydralazine; Injections, Intravenous; Isosorbide Dinitrate; Male; Middle Aged; Myocardial Infarction; Prazosin; Pulmonary Wedge Pressure; Vasodilator Agents; Ventricular Function, Left | 1992 |
Treatment of patients with heart failure.
Topics: Arrhythmias, Cardiac; Cardiac Output, Low; Humans; Hydralazine; Isosorbide Dinitrate | 1990 |
Can we expect vasodilator therapy to prolong life in patients with congestive heart failure?
Topics: Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Time Factors; Vasodilator Agents | 1987 |
Clinical pharmacology of vasodilator drugs.
Topics: Adrenergic alpha-Antagonists; Calcium Channel Blockers; Coronary Disease; Humans; Hydralazine; Hypertension; Isosorbide Dinitrate; Kinetics; Liver; Muscle Contraction; Muscle, Smooth, Vascular; Nitroglycerin; Prazosin; Vasodilator Agents; Verapamil | 1985 |
Current indications for vasodilator therapy for left ventricular failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Minoxidil; Myocardial Infarction; Nitroprusside; Prazosin; Vasodilator Agents | 1985 |
[Long-term vasodilator therapy of chronic refractory heart failure in patients with dilated cardiomyopathy].
Topics: Adult; Aged; Cardiomyopathy, Dilated; Chronic Disease; Drug Therapy, Combination; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Long-Term Care; Male; Middle Aged; Todralazine; Vasodilator Agents | 1986 |
Role of nitrates in congestive heart failure.
Topics: Dosage Forms; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Nitroglycerin | 1987 |
[Systolic intervals in dilated heart insufficiency. Influence of vasodilator treatment].
Topics: Aged; Captopril; Female; Heart Failure; Heart Ventricles; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Myocardial Contraction; Systole; Vasodilator Agents | 1988 |
Effects of captopril and a combination of hydralazine and isosorbide dinitrate on myocardial sympathetic tone in patients with severe congestive heart failure.
Topics: Aged; Blood Pressure; Captopril; Drug Therapy, Combination; Epinephrine; Female; Heart Failure; Heart Rate; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Norepinephrine; Pulmonary Wedge Pressure; Vascular Resistance | 1986 |
[Effect of peripheral vasodilators on thrombocyte aggregation in chronic circulatory insufficiency].
Topics: Adult; Aged; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Platelet Aggregation; Vasodilator Agents | 1986 |
[Peripheral vasodilator in cardiac insufficiency in the acute period of myocardial infarction].
Topics: Cardiomyopathy, Dilated; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Myocardial Infarction; Nifedipine; Vasodilator Agents | 1985 |
Effect of certain drugs on perfused human placenta. 8. Angiotensin-II antagonists.
Topics: Acetates; Angiotensin II; Atropine; Blood Pressure Determination; Cobalt; Cocaine; Cyproheptadine; Dibenzylchlorethamine; Dipyridamole; Ethanol; Female; Furans; Glycols; Humans; Hydralazine; In Vitro Techniques; Isosorbide Dinitrate; Muscles; Nitrates; Nitrites; Nitroglycerin; Papaverine; Perfusion; Phentolamine; Placenta; Pregnancy; Sodium; Sympatholytics; Tartrates; Tolazoline | 1968 |
[Vasodilator drugs in the therapy of chronic congestive heart failure. Clinico-case contribution].
Topics: Blood Pressure; Cardiomegaly; Chronic Disease; Drug Evaluation; Heart; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Vasodilator Agents | 1983 |
Vasodilators in the treatment of congestive heart failure.
Topics: Captopril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Minoxidil; Nitroglycerin; Nitroprusside; Prazosin; Vasodilator Agents | 1983 |
Ambulatory long-term vasodilator therapy for chronic refractory heart failure: hemodynamic evaluation and clinical response.
Topics: Adult; Aged; Ambulatory Care; Cardiac Catheterization; Cardiomyopathy, Dilated; Chronic Disease; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Hydrazines; Isosorbide Dinitrate; Long-Term Care; Male; Middle Aged; Mitral Valve Insufficiency; Stroke Volume; Todralazine | 1984 |
Nitrates in heart failure. Pathophysiological mechanisms and therapeutic applications.
Topics: Cardiac Output; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Muscle, Smooth, Vascular; Myocardium; Nitrates; Nitroglycerin; Oxygen Consumption; Pulmonary Wedge Pressure; Vasodilation | 1984 |
Nitrates in acute myocardial infarction.
Topics: Blood Pressure; Cardiac Output; Drug Interactions; Furosemide; Heart Failure; Heart Rate; Humans; Hydralazine; Isosorbide Dinitrate; Myocardial Infarction; Vascular Resistance | 1984 |
Adjuvant therapy of chronic refractory cardiac failure with oral hydralazine and isosorbide dinitrate.
Topics: Administration, Oral; Adolescent; Adult; Aged; Chronic Disease; Digoxin; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Vasodilator Agents | 1983 |
Contrasting hemodynamic responses in severe heart failure: comparison of captopril and other vasodilator drugs.
Topics: Adult; Aged; Captopril; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Lung; Male; Middle Aged; Nitroprusside; Prazosin; Proline; Vascular Resistance; Vasodilation; Vasodilator Agents | 1982 |
Postural hypotension and tachycardia during hydralazine--isosorbide dinitrate therapy for chronic heart failure.
Topics: Heart Failure; Hemodynamics; Humans; Hydralazine; Hypotension, Orthostatic; Isosorbide Dinitrate; Long-Term Care; Tachycardia; Vasodilator Agents | 1981 |
Vasodilator therapy in refractory congestive heart failure: a comparative analysis of hemodynamic and noninvasive studies.
Topics: Aged; Cardiac Output; Drug Evaluation; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Nitroglycerin; Ointment Bases; Prazosin; Pulmonary Wedge Pressure; Stroke Volume; Vasodilator Agents | 1982 |
Baroreflex response and vasodilating drugs in essential hypertension.
Topics: Adult; Benzazepines; Blood Pressure; Brachial Artery; Dihydralazine; Diltiazem; Heart Rate; Humans; Hydralazine; Hypertension; Isosorbide Dinitrate; Male; Middle Aged; Pressoreceptors; Reflex; Vascular Resistance | 1983 |
Hemodynamic and metabolic effects of vasodilators, nitrates, hydralazine, prazosin and captopril in chronic ischemic heart failure.
Topics: Captopril; Coronary Disease; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Lactates; Myocardium; Oxygen Consumption; Prazosin; Vasodilator Agents | 1981 |
Vasodilators in heart failure secondary to coronary artery disease.
Topics: Cardiac Output; Coronary Disease; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Myocardium; Oxygen Consumption; Prazosin; Pulmonary Wedge Pressure; Time Factors; Vasodilator Agents | 1982 |
Hemodynamic effects of vasodilator therapy in severe left heart failure combined with large atrial septal defects.
Topics: Blood Pressure; Heart Failure; Heart Septal Defects, Atrial; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Vascular Resistance; Vasodilator Agents | 1982 |
Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension.
Topics: Adolescent; Adult; Aspirin; Diazoxide; Dipyridamole; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Indomethacin; Isoproterenol; Isosorbide Dinitrate; Middle Aged; Phentolamine; Prostaglandin Antagonists; Tolazoline; Vascular Resistance; Vasodilator Agents | 1982 |
Reassessment of vasodilator therapy in angina: effects of oral isosorbide dinitrate and hydralazine on exercise tolerance in patients receiving propranolol.
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Exercise Test; Heart Rate; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Propranolol; Time Factors; Vasodilator Agents | 1981 |
Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure.
Topics: Adult; Aged; Chronic Disease; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Middle Aged; Physical Exertion | 1981 |
Results of long-term vasodilator therapy in patients with refractory congestive heart failure.
Topics: Administration, Oral; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Myocardial Infarction; Vasodilator Agents | 1981 |
Effects of isosorbide dinitrate and hydralazine on regional metabolic responses to arm exercise in patients with heart failure.
Topics: Adult; Arm; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Lactates; Lactic Acid; Male; Middle Aged; Muscles; Oxygen Consumption; Physical Exertion | 1981 |
Combined vasodilator therapy in the treatment of chronic heart failure.
Topics: Blood Pressure; Drug Therapy, Combination; Heart Failure; Heart Rate; Humans; Hydralazine; Isosorbide Dinitrate | 1981 |
Is there a drug of choice for vasodilator therapy in patients with refractory heart failure?
Topics: Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Phentolamine; Prazosin; Vasodilator Agents | 1980 |
Effects of vasodilators on pulmonary hemodynamics and gas exchange in left ventricular failure.
Topics: Adult; Aged; Blood Gas Analysis; Blood Pressure; Ferricyanides; Heart Failure; Heart Rate; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Lung; Male; Middle Aged; Nitroprusside; Respiratory Function Tests; Stroke Volume; Vasodilator Agents | 1980 |
Hydralazine and isosorbide dinitrate: comparative central and regional hemodynamic effects when administered alone or in combination.
Topics: Adult; Aged; Arm; Blood Pressure; Cardiac Output; Drug Therapy, Combination; Female; Heart Rate; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Kidney; Liver; Male; Middle Aged; Pulmonary Wedge Pressure; Stroke Volume; Vascular Resistance | 1981 |
Ventricular wall thickness: a predictor of response to vasodilators in cardiomyopathy.
Topics: Administration, Oral; Adult; Cardiomyopathies; Follow-Up Studies; Heart Ventricles; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Middle Aged; Prognosis; Vasodilator Agents | 1980 |
Effects of nitric oxide-related agents on rat testicular function.
Topics: Amino Acid Oxidoreductases; Animals; Arginine; Drug Interactions; Hydralazine; Isosorbide Dinitrate; Male; NG-Nitroarginine Methyl Ester; Nicardipine; Nitric Oxide; Nitric Oxide Synthase; Rats; Rats, Sprague-Dawley; Steroids; Stimulation, Chemical; Testis; Testosterone; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 1994 |
Effect of beraprost sodium, a stable prostacyclin analogue, on pulmonary thromboembolism in mice.
Topics: Administration, Oral; Alprostadil; Animals; Aspirin; Bridged Bicyclo Compounds; Collagen; Diltiazem; Drug Evaluation, Preclinical; Epinephrine; Epoprostenol; Fatty Acids, Monounsaturated; Fibrinolytic Agents; Heparin; Hydralazine; Injections, Intravenous; Isosorbide Dinitrate; Male; Mice; Nifedipine; Nitroprusside; Platelet Aggregation Inhibitors; Pulmonary Embolism; Superoxide Dismutase; Vasodilator Agents | 1995 |
Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Cardiotonic Agents; Cohort Studies; Contraindications; Female; Hospitalization; Humans; Hydralazine; Hyperkalemia; Isosorbide Dinitrate; Male; Medicare; Middle Aged; Multivariate Analysis; Patient Discharge; Peer Review, Health Care; Professional Review Organizations; Renal Insufficiency; Retrospective Studies; Stroke Volume; United States; United States Agency for Healthcare Research and Quality; Vasodilator Agents | 1997 |
Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Captopril; Cardiac Output; Diuretics; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Vasodilator Agents; Ventricular Pressure | 1997 |
The AHCPR clinical practice guideline for heart failure revisited.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Calcium Channel Blockers; Cardiac Output, Low; Digoxin; Diuretics; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Ventricular Dysfunction, Left | 1997 |
K-Cl cotransport in vascular smooth muscle and erythrocytes: possible implication in vasodilation.
Topics: Alkaloids; Animals; Aorta; Biological Transport; Carbazoles; Carrier Proteins; Cells, Cultured; Chlorides; Coronary Vessels; Enzyme Inhibitors; Erythrocytes; Ethylmaleimide; Genistein; Hydralazine; Indoles; Isometric Contraction; Isosorbide Dinitrate; K Cl- Cotransporters; Marine Toxins; Muscle, Smooth, Vascular; Nitric Oxide; Nitroprusside; Oxazoles; Potassium; Propylene Glycols; Rats; Rubidium; Sheep; Swine; Symporters; Vasoconstriction; Vasodilation; Vasodilator Agents | 2000 |
Tailored treatments.
Topics: Black or African American; Cardiovascular Agents; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate | 2001 |
Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Fibrillation; Dogs; Electrophysiology; Enalapril; Endomyocardial Fibrosis; Heart Atria; Heart Failure; Hemodynamics; Hydralazine; Isosorbide Dinitrate; Mitogen-Activated Protein Kinases; Renin-Angiotensin System; Signal Transduction; Tachycardia, Ventricular | 2001 |
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Data Interpretation, Statistical; Double-Blind Method; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Weight Loss | 2003 |
Getting the numbers right: statistical mischief and racial profiling in heart failure research.
Topics: Adult; Aged; Black or African American; Clinical Trials as Topic; Data Interpretation, Statistical; Drug Combinations; Epidemiologic Research Design; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Prejudice; Socioeconomic Factors; United States; White People | 2003 |
Race-based therapeutics.
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Drug Approval; Drug Combinations; Drug Industry; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitric Oxide Donors; Patents as Topic; Pharmacogenetics; United States; United States Food and Drug Administration; Vasodilator Agents | 2004 |
Nitroso-redox balance in the cardiovascular system.
Topics: Black People; Cardiovascular System; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Oxidation-Reduction; Signal Transduction; Superoxides; Vasodilator Agents | 2004 |
Postcards: race and medicine in the 21st century.
Topics: Black or African American; Clinical Trials as Topic; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; United States | 2004 |
Color blind.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Prejudice; Racial Groups; Therapeutics | 2004 |
Studying treatment of heart failure in blacks.
Topics: Black People; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Marketing; Prevalence; Research Design; United States | 2005 |
A cure for a race? Heart drug findings set off ethics debate.
Topics: Black or African American; Clinical Trials as Topic; Drug Combinations; Drug Therapy, Combination; Drugs, Investigational; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Marketing of Health Services; Pharmacogenetics; Racial Groups; Treatment Outcome; United States | 2004 |
The year in heart failure: 2004.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Defibrillators, Implantable; Disease Management; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Monitoring, Physiologic; Prognosis; Treatment Outcome; Vasodilator Agents; Ventricular Remodeling | 2005 |
Medicine. Race and reification in science.
Topics: Bias; Cardiovascular Agents; Crime; Databases, Nucleic Acid; Drug Combinations; Forensic Sciences; Gene Frequency; Genetic Variation; Genetics, Medical; Heart Diseases; Humans; Hydralazine; Hypertension; Isosorbide Dinitrate; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Racial Groups | 2005 |
Isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Black People; Coronary Disease; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Hypertension; Isosorbide Dinitrate; Vasodilator Agents | 2005 |
Isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Black People; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Lupus Erythematosus, Systemic; Vasodilator Agents | 2005 |
Isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Black People; Data Interpretation, Statistical; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Vasodilator Agents | 2005 |
Isosorbide dinitrate and hydralazine in blacks with heart failure.
Topics: Black People; Calcium Channel Blockers; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Hypertension; Isosorbide Dinitrate; Vasodilator Agents | 2005 |
Race and a heart drug.
Topics: Black People; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Multicenter Studies as Topic; Nitric Oxide; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Vasodilator Agents; White People | 2005 |
Pharmacogenetics and ethnically targeted therapies.
Topics: Drug Combinations; Humans; Hydralazine; Isosorbide Dinitrate; Pharmacogenetics; Racial Groups | 2005 |
U.S. to review drug intended for one race.
Topics: Black or African American; Cardiovascular Agents; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Industry; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Marketing of Health Services; Pharmacogenetics; Racial Groups; United States; United States Food and Drug Administration | 2005 |
Drug targeting: is race enough?
Topics: Asian People; Black or African American; Drug Combinations; Drug Industry; ErbB Receptors; Gefitinib; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Pharmacogenetics; Quinazolines; United States; United States Food and Drug Administration | 2005 |
Pharmacogenetics and ethnically targeted therapies: racial drugs need to be put in context.
Topics: Conflict of Interest; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Pharmacogenetics; Racial Groups | 2005 |
F.D.A. panel approves heart remedy for blacks.
Topics: Advisory Committees; Black or African American; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; United States; United States Food and Drug Administration | 2005 |
F.D.A. approves a heart drug for African-Americans.
Topics: Black or African American; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; United States; United States Food and Drug Administration | 2005 |
Misreading race and genomics after BiDil.
Topics: Black or African American; Cardiovascular Agents; Drug Approval; Drug Combinations; Genomics; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; United States; United States Food and Drug Administration | 2005 |
Race, drugs, and heart failure.
Topics: Aged; Aged, 80 and over; Black People; Drug Combinations; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome; United States; Vasodilator Agents | 2005 |
Color blind, or just plain blind?
Topics: Arginine; Black People; Delayed-Action Preparations; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitric Oxide; Pharmacogenetics; Vasodilator Agents | 2005 |
Maker of heart drug intended for blacks bases price on patients' wealth.
Topics: Black or African American; Costs and Cost Analysis; Drug Combinations; Drug Costs; Drug Industry; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Marketing; Socioeconomic Factors; United States | 2005 |
Illuminating BiDil.
Topics: Black or African American; Drug Approval; Drug Combinations; Genetic Predisposition to Disease; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Politics; Public Policy; United States | 2005 |
New heart-failure therapy takes race into account.
Topics: Black People; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2005 |
Drug success signals a new trend. A "race-based" medication is a step toward individualized care.
Topics: Black People; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitric Oxide; Vasodilator Agents | 2005 |
Drugs tailored to race move a step closer to reality.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Pharmacogenetics | 2005 |
BiDil for heart failure.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Black People; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Vasodilator Agents | 2005 |
Race as a proxy for drug response: the dangers and challenges of ethnic drugs.
Topics: Black or African American; Clinical Trials as Topic; Commerce; Conflict of Interest; Drug Combinations; Drug Industry; Ethnicity; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Pharmacogenetics; Racial Groups | 2004 |
Update on outpatient treatment of systolic heart failure.
Topics: Ambulatory Care; Black or African American; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Spironolactone; Treatment Outcome; Vasodilator Agents | 2005 |
Approval of drug marketed to African Americans raises political, economic issues. Study criticizes manufacturer for re-branding generic drug with race-specific indication.
Topics: Black or African American; Drug Approval; Drug Combinations; Drug Industry; Economics; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Marketing; Politics; United States; United States Food and Drug Administration | 2005 |
BiDil's impact.
Topics: Black or African American; Drug Approval; Drug Combinations; Genetic Predisposition to Disease; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Risk; United States | 2005 |
On the selling of pharmaceuticals.
Topics: Commerce; Drug Combinations; Hydralazine; Isosorbide Dinitrate; Pharmaceutical Preparations | 2005 |
Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure.
Topics: Black People; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; Heart Failure; Hospitalization; Humans; Hydralazine; Isosorbide Dinitrate; Length of Stay; Male; Middle Aged; Randomized Controlled Trials as Topic; Retrospective Studies | 2005 |
Gray area for new heart failure drug. Although the FDA approved BiDil for blacks with heart failure, it may work in anyone.
Topics: Black People; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitric Oxide; Pharmacogenetics; Racial Groups | 2005 |
A look back at the most influential drug approvals of 2005.
Topics: Amyloid; Analgesics; Anticonvulsants; Antiparkinson Agents; Diabetes Mellitus, Type 2; Diphtheria-Tetanus-Pertussis Vaccine; Drug Approval; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Exenatide; gamma-Aminobutyric Acid; Heart Failure; Humans; Hydralazine; Hypoglycemic Agents; Indenes; Indoles; Islet Amyloid Polypeptide; Isosorbide Dinitrate; Patient Education as Topic; Patient Selection; Peptides; Pregabalin; Sleep Wake Disorders; United States; United States Food and Drug Administration; Venoms | 2006 |
The isosorbide-hydralazine story: is there a case for race-based cardiovascular medicine?
Topics: Antihypertensive Agents; Black or African American; Diuretics, Osmotic; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitric Oxide Synthase; Risk Assessment; Socioeconomic Factors; United States | 2006 |
"Racially-tailored" medicine unraveled.
Topics: Cardiovascular Agents; Civil Rights; Delivery of Health Care; Drug Combinations; Ethics Committees, Research; Federal Government; Financing, Government; Genetic Research; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; National Institutes of Health (U.S.); Organizational Policy; Patient Rights; Pharmacogenetics; Prejudice; Racial Groups; State Government; United States | 2005 |
Novel heart failure drug may offer options for you.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Vasodilator Agents | 2005 |
Food & Drug Administration panel approves heart failure medication aimed at African-Americans.
Topics: Advisory Committees; Black or African American; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; United States; United States Food and Drug Administration; Vasodilator Agents | 2005 |
Using race in clinical research to develop tailored medications. Is the FDA encouraging discrimination or eliminating traditional disparities in health care for African Americans?
Topics: Black or African American; Clinical Protocols; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Industry; Drugs, Investigational; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Patient Selection; Pharmacogenetics; Prejudice; Socioeconomic Factors; Supreme Court Decisions; Treatment Outcome; United States; United States Food and Drug Administration; Vasodilator Agents | 2006 |
Prescribing BiDil: is it black and white?
Topics: Angiotensin-Converting Enzyme Inhibitors; Black People; Drug Approval; Drug Combinations; Enalapril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Treatment Outcome; United States; United States Food and Drug Administration; White People | 2006 |
Diagnosis and management of chronic heart failure.
Topics: Adult; Drug Therapy, Combination; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Practice Guidelines as Topic; Vasodilator Agents | 2006 |
Response to the February 2006 Journal of Cardiac Failure Editor's comment.
Topics: Black or African American; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate | 2006 |
Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial.
Topics: Aged; Alleles; Black or African American; Cardiac Output, Low; Cohort Studies; Cytochrome P-450 CYP11B2; Female; Genotype; Heterozygote; Homozygote; Hospitalization; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Polymorphism, Genetic; Predictive Value of Tests; Promoter Regions, Genetic; Survival Analysis; Treatment Outcome; Vasodilator Agents; Ventricular Remodeling | 2006 |
The use of race and ethnicity in medicine: lessons from the African-American Heart Failure Trial.
Topics: Biomedical Research; Black or African American; Civil Rights; Drug Combinations; Ethical Analysis; Evidence-Based Medicine; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Patient Selection; Pharmacogenetics; Prejudice; Randomized Controlled Trials as Topic; United States; Vasodilator Agents | 2006 |
Race, money and medicines.
Topics: Biomedical Research; Civil Rights; Drug Approval; Drug Combinations; Drug Industry; Ethical Analysis; Ethnicity; Health Care Costs; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Patient Selection; Prejudice; Racial Groups; Randomized Controlled Trials as Topic; Sociology, Medical; United States; United States Food and Drug Administration; Vasodilator Agents | 2006 |
Outcomes by gender in the African-American Heart Failure Trial.
Topics: Adult; Aged; Black or African American; Cardiac Output, Low; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Sex Factors; Survival Analysis; Time Factors; Treatment Outcome; Vasodilator Agents | 2006 |
BiDil for heart failure in black patients: implications of the U.S. Food and Drug Administration approval.
Topics: Black People; Cardiovascular Agents; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Public Policy; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2007 |
BiDil for heart failure in black patients: The U.S. Food and Drug Administration perspective.
Topics: Black People; Cardiovascular Agents; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Public Policy; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2007 |
Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.
Topics: Adult; Aged; Antihypertensive Agents; Black or African American; Blood Pressure; Comorbidity; Drug Combinations; Female; Heart Failure; Humans; Hydralazine; Hypotension; Isosorbide Dinitrate; Male; Middle Aged; Randomized Controlled Trials as Topic; Systole; Treatment Outcome; Vasodilator Agents | 2007 |
Editorial commentary on fixed combination isosorbide dinitrate/hydralazine for nitric-oxide-enhancing therapy in heart failure.
Topics: Black or African American; Chemistry, Pharmaceutical; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitric Oxide Donors | 2007 |
From disparity to difference: how race-specific medicines may undermine policies to address inequalities in health care.
Topics: Black or African American; Drug Combinations; Ethnicity; Health Policy; Health Services Accessibility; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Pharmacogenetics; Prejudice; Social Justice; Socioeconomic Factors; United States | 2005 |
There is no scientific rationale for race-based research.
Topics: Biomarkers; Biomedical Research; Black or African American; Clinical Trials as Topic; Drug Combinations; Genetic Predisposition to Disease; Genetic Variation; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Prejudice; Racial Groups; United States | 2007 |
What's right (and wrong) with racially stratified research and therapies.
Topics: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biomedical Research; Black or African American; Drug Approval; Drug Combinations; Drug Industry; Genetic Predisposition to Disease; Genetic Variation; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Prejudice; Racial Groups; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2007 |
BiDil: primary care physicians first and cardiologist when?
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black or African American; Cardiology; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Practice Guidelines as Topic; Primary Health Care; Ventricular Dysfunction, Left | 2007 |
The paradox of race in the Bidil debate.
Topics: Black or African American; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Racial Groups; Social Identification; United States; United States Food and Drug Administration | 2007 |
BiDil for heart failure in black patients.
Topics: Black People; Cardiovascular Agents; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; United States; United States Food and Drug Administration | 2007 |
BiDil for heart failure in black patients.
Topics: Black People; Cardiovascular Agents; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; United States; United States Food and Drug Administration | 2007 |
Race in a bottle. Drugmakers are eager to develop medicines targeted at ethnic groups, but so far they have made poor choices based on unsound science.
Topics: Black or African American; Drug Combinations; Drug Design; Ethnicity; Heart Diseases; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate | 2007 |
Bidil: recontextualizing the race debate.
Topics: Black or African American; Clinical Trials as Topic; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Pharmacogenetics; Racial Groups; United States; United States Food and Drug Administration | 2008 |
BiDil flops.
Topics: Black People; Drug Industry; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Marketing; Massachusetts; Patents as Topic | 2008 |
Introduction: Facts and fictions: BiDil and the resurgence of racial medicine.
Topics: Black People; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Vasodilator Agents | 2008 |
Flaws in the U.S. Food and Drug Administration's rationale for supporting the development and approval of BiDil as a treatment for heart failure only in black patients.
Topics: Black People; Drug Approval; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; United States; United States Food and Drug Administration; Vasodilator Agents | 2008 |
"Special treatment": BiDil, Tuskegee, and the logic of race.
Topics: Black or African American; Clinical Trials as Topic; Drug Approval; Drug Combinations; Ethics, Medical; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Prejudice; Racial Groups; Syphilis; Vasodilator Agents; Withholding Treatment | 2008 |
Popular representations of race: the news coverage of BiDil.
Topics: Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Mass Media; Racial Groups; Vasodilator Agents | 2008 |
Exploring the potential synergistic action of spironolactone on nitric oxide-enhancing therapy: insights from the African-American Heart Failure Trial.
Topics: Adult; Aged; Black or African American; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Synergism; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Multicenter Studies as Topic; Nitric Oxide Donors; Randomized Controlled Trials as Topic; Retrospective Studies; Spironolactone | 2008 |
From the editors.
Topics: Analgesia; Bioethical Issues; Bioethics; Black or African American; Conscience; Drug Combinations; Ethics, Clinical; Heart Failure; Humans; Hydralazine; Interdisciplinary Communication; Isosorbide Dinitrate; Liver Diseases, Alcoholic; Liver Transplantation; Morals; Neurosciences; Patient-Centered Care; Persistent Vegetative State; Social Sciences; United States; United States Food and Drug Administration; Waiting Lists | 2009 |
Race-based medicine and justice as recognition: exploring the phenomenon of BiDil.
Topics: Black or African American; Cardiovascular Agents; Drug Approval; Drug Combinations; Drug Design; Ethical Theory; Healthcare Disparities; Heart Failure; History, 20th Century; History, 21st Century; Humans; Hydralazine; Isosorbide Dinitrate; Social Justice; United States | 2009 |
Pharmacogenetics, race and global injustice.
Topics: Black or African American; Delivery of Health Care; Developing Countries; Drug Combinations; Heart Failure; Humans; Hydralazine; Internationality; Isosorbide Dinitrate; Pharmacogenetics; Racial Groups; Social Justice; United States; United States Food and Drug Administration | 2008 |
Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Interactions; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Pregnancy; Vasodilator Agents; Ventricular Dysfunction, Left | 2008 |
Exploiting race in drug development: BiDil's interim model of pharmacogenomics.
Topics: Cardiovascular Agents; Drug Combinations; History, 20th Century; History, 21st Century; Humans; Hydralazine; Intellectual Property; Isosorbide Dinitrate; Pharmacogenetics; Racial Groups; United States; United States Food and Drug Administration | 2008 |
Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged | 2009 |
Have we witnessed the rise and fall of race-specific drugs?
Topics: Black or African American; Drug Combinations; Heart Failure; Hispanic or Latino; Humans; Hydralazine; Isosorbide Dinitrate; Patient Selection; Risk Assessment; Risk Factors; Treatment Outcome; Vasodilator Agents; White People | 2009 |
Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure.
Topics: Aged; Black or African American; Drug Combinations; Drug Prescriptions; Female; Heart Failure; Hispanic or Latino; Hospitalization; Humans; Hydralazine; Isosorbide Dinitrate; Male; Patient Selection; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Vasodilator Agents; Veterans; White People | 2009 |
Effects of fixed-dose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Blood Pressure; Cytokines; Diastole; Drug Therapy, Combination; Echocardiography, Doppler; Exercise Test; Fibrosis; Gene Expression; Heart; Heart Failure; Hydralazine; Hypertension; Isosorbide Dinitrate; Male; Mice; Myocardium; Reverse Transcriptase Polymerase Chain Reaction; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium Chloride, Dietary; Vascular Cell Adhesion Molecule-1; Vasodilator Agents | 2009 |
Dysfunctional corin i555(p568) allele is associated with impaired brain natriuretic peptide processing and adverse outcomes in blacks with systolic heart failure: results from the Genetic Risk Assessment in Heart Failure substudy.
Topics: Black or African American; Cardiovascular Agents; Double-Blind Method; Drug Combinations; Female; Gene Frequency; Genetic Predisposition to Disease; Heart Failure, Systolic; Hospitalization; Humans; Hydralazine; Immunoassay; Isosorbide Dinitrate; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Mutation; Natriuretic Peptide, Brain; Phenotype; Proportional Hazards Models; Protein Processing, Post-Translational; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Serine Endopeptidases; Treatment Outcome; United States | 2009 |
Primary care physicians' attitudes regarding race-based therapies.
Topics: Adult; Aged; Attitude of Health Personnel; Black People; Drug Combinations; Female; Focus Groups; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Physician-Patient Relations; Physicians, Primary Care; Racial Groups; White People | 2010 |
Isosorbide dinitrate and hydralazine as therapy for African Americans with heart failure; a failed paradigm?
Topics: Black or African American; Cardiology; Drug Combinations; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Models, Theoretical; Polymorphism, Genetic; Translational Research, Biomedical; Treatment Outcome | 2009 |
Grassroots marketing in a global era: more lessons from BiDil.
Topics: Black People; Drug Combinations; Drug Industry; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Marketing; Pharmacogenetics | 2011 |
Question: does isosorbide dinitrate/hydralazine therapy benefit systolic heart failure patients with renal insufficiency?
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Drug Combinations; Evidence-Based Medicine; Heart Failure, Systolic; Hemodynamics; Humans; Hydralazine; Isosorbide Dinitrate; Randomized Controlled Trials as Topic; Renal Insufficiency; Treatment Outcome | 2011 |
Letter by Taylor et al regarding article, "Hydralazine and isosorbide dinitrate in heart failure: historical perspectives, mechanisms, and future directions".
Topics: Animals; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate | 2011 |
The short life of a race drug.
Topics: Black or African American; Drug Combinations; Humans; Hydralazine; Isosorbide Dinitrate; Precision Medicine; United States; United States Food and Drug Administration; Vasodilator Agents | 2012 |
A race-based detour to personalized medicine.
Topics: Black People; Genetics, Medical; Heart Diseases; Humans; Hydralazine; Isosorbide Dinitrate; Pharmacogenetics; Precision Medicine; Racial Groups; United States | 2012 |
Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction.
Topics: Aged; Aged, 80 and over; Black or African American; Chi-Square Distribution; Drug Combinations; Drug Utilization Review; Female; Guideline Adherence; Healthcare Disparities; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Logistic Models; Male; Middle Aged; Multivariate Analysis; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Registries; Stroke Volume; Time Factors; Treatment Outcome; United States; Vasodilator Agents; Ventricular Function, Left | 2013 |
Genetic mechanisms possibly leading to racially different responses to nitrate therapy.
Topics: Black or African American; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate | 2014 |
Current perspectives on hydralazine and nitrate therapies in heart failure.
Topics: Age Factors; Drug Combinations; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Randomized Controlled Trials as Topic; Sex Factors | 2014 |
Polymorphic variation in the G-protein beta-3 subunit gene and response to BiDil in A-HeFT: Basis for an African-American pharmacogenetic advantage to nitric oxide donor therapy?
Topics: Female; Heart Failure; Heterotrimeric GTP-Binding Proteins; Humans; Hydralazine; Isosorbide Dinitrate; Male; Polymorphism, Single Nucleotide; Vasodilator Agents | 2014 |
Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry.
Topics: Aged; Aged, 80 and over; Chi-Square Distribution; Disease Progression; Drug Combinations; Female; Guideline Adherence; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Kaplan-Meier Estimate; Logistic Models; Male; Medicare Part D; Patient Discharge; Patient Readmission; Practice Guidelines as Topic; Practice Patterns, Physicians'; Proportional Hazards Models; Registries; Risk Factors; Stroke Volume; Time Factors; Treatment Outcome; United States | 2016 |
Making Medicine Precise and Personalized: What Can We Learn from the Past?
Topics: Female; Guideline Adherence; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Practice Guidelines as Topic; Practice Patterns, Physicians'; Stroke Volume | 2016 |
PGX: Pharmacogenomics During Generation X.
Topics: Anticoagulants; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Pharmaceutical Preparations; Pharmacogenetics; Pharmacogenomic Variants; Pharmacokinetics; Precision Medicine; Pulmonary Embolism; Renal Insufficiency, Chronic; Stroke | 2016 |
Dilemmas With Race and Heart Failure Treatment.
Topics: Black or African American; Clinical Decision-Making; Drug Combinations; Health Status Disparities; Healthcare Disparities; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Patient Selection; Treatment Outcome; United States; Vasodilator Agents | 2016 |
Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure.
Topics: Adult; Black or African American; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Kaplan-Meier Estimate; Male; Medicare; Middle Aged; Off-Label Use; Prospective Studies; Retrospective Studies; United States | 2017 |
Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in African-American Patients With Heart Failure.
Topics: Adult; Aged; Black or African American; Cardiotonic Agents; Drug Combinations; Female; Heart Failure; Humans; Hydralazine; Incidence; Isosorbide Dinitrate; Male; Middle Aged; Treatment Outcome; United States; Young Adult | 2017 |
The Paradox in Demonstrating Hydralazine-Nitrate Efficacy.
Topics: Black or African American; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Treatment Outcome | 2017 |
Adherence to the evidence-based heart failure drug treatment: Are there sex-specific differences among new users?
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Drug Combinations; Evidence-Based Medicine; Female; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Medication Adherence; Middle Aged; Sex Factors; Young Adult | 2018 |
Underuse of hydralazine and isosorbide dinitrate for heart failure in patients of African ancestry: a cross-European survey.
Topics: Black People; Cardiovascular Agents; Cross-Sectional Studies; Databases, Pharmaceutical; Drug Combinations; Drug Prescriptions; Europe; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate | 2019 |
Drug-induced Hemolysis in G6PD Deficiency: an Unusual Presentation of a Common Clinical Condition.
Topics: Cardiovascular Agents; Drug Combinations; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged | 2019 |
Captopril Versus Hydralazine-Isosorbide Dinitrate Vasodilator Protocols in Patients With Acute Decompensated Heart Failure Transitioning From Sodium Nitroprusside.
Topics: Adult; Aftercare; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Nitroprusside; Patient Discharge; Retrospective Studies; Vasodilator Agents | 2021 |
Vericiguat, organic nitrates, and heart failure in African Americans.
Topics: Black or African American; Heart Failure; Heterocyclic Compounds, 2-Ring; Humans; Hydralazine; Isosorbide Dinitrate; Nitrates; Pyrimidines; Stroke Volume | 2021 |
Cardiologists' Perspectives on BiDil and the Use of Race in Drug Prescribing.
Topics: Cardiologists; Cross-Sectional Studies; Drug Prescriptions; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate | 2022 |
When the Whole Is the Sum of Its Parts: Validation of the Heart Failure Collaboratory Medication Composite Score in Denmark.
Topics: Denmark; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate | 2023 |